USANA Capital Surpluse vs Deferred Long Term Liab Analysis

USNA Stock

USD 39.92 0.02 0.05%

USANA Health financial indicator trend analysis is much more than just breaking down USANA Health Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether USANA Health Sciences is a good investment. Please check the relationship between USANA Health Capital Surpluse and its Deferred Long Term Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Capital Surpluse vs Deferred Long Term Liab

Capital Surpluse vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of USANA Health Sciences Capital Surpluse account and Deferred Long Term Liab. At this time, the significance of the direction appears to have no relationship.

The correlation between USANA Health's Capital Surpluse and Deferred Long Term Liab is 0.02. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of USANA Health Sciences, assuming nothing else is changed. The correlation between historical values of USANA Health's Capital Surpluse and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of USANA Health Sciences are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Capital Surpluse i.e., USANA Health's Capital Surpluse and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.02

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capital Surpluse

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from USANA Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into USANA Health Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At present, USANA Health's Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.36, whereas Selling General Administrative is forecasted to decline to about 220.8 M.

	2021	2022	2023	2024 (projected)
Gross Profit	968.6M	804.7M	744.3M	475.7M
Total Revenue	1.2B	998.6M	921.0M	585.9M

Gross Profit Total Revenue

USANA Health fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Long Term Debt Total	Current Deferred Revenue	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Short Term Debt	Common Stock
Common Stock Shares Outstanding		-0.9	-0.71	-0.89	-0.86	-0.93	0.85	-0.84	-0.82	-0.82	-0.95	-0.7	-0.81	-0.87	-0.32	-0.7	-0.91	-0.66	-0.86	-0.53	-0.78	-0.32	0.73	-0.75	-0.01	0.73
Total Assets	-0.9		0.6	0.79	0.99	0.81	-0.97	0.98	0.77	0.96	0.77	0.79	0.97	0.78	0.22	0.58	0.81	0.78	0.99	0.61	0.65	0.29	-0.68	0.69	0.06	-0.68
Other Current Liab	-0.71	0.6		0.89	0.51	0.88	-0.49	0.44	0.69	0.43	0.81	0.14	0.44	0.78	0.77	0.92	0.86	0.17	0.55	0.31	0.85	0.8	-0.71	0.44	0.57	-0.71
Total Current Liabilities	-0.89	0.79	0.89		0.7	0.95	-0.71	0.66	0.87	0.66	0.91	0.45	0.68	0.96	0.5	0.81	0.99	0.34	0.77	0.3	0.82	0.54	-0.68	0.71	0.25	-0.68
Total Stockholder Equity	-0.86	0.99	0.51	0.7		0.74	-0.97	0.99	0.69	0.98	0.7	0.82	0.98	0.7	0.15	0.51	0.72	0.85	0.98	0.66	0.58	0.22	-0.64	0.63	0.02	-0.64
Property Plant And Equipment Net	-0.93	0.81	0.88	0.95	0.74		-0.73	0.7	0.82	0.68	0.96	0.45	0.68	0.9	0.5	0.86	0.94	0.47	0.76	0.48	0.84	0.52	-0.76	0.66	0.26	-0.77
Net Debt	0.85	-0.97	-0.49	-0.71	-0.97	-0.73		-0.98	-0.72	-1.0	-0.68	-0.85	-0.99	-0.69	-0.05	-0.47	-0.73	-0.82	-0.98	-0.57	-0.51	-0.15	0.52	-0.68	0.1	0.52
Retained Earnings	-0.84	0.98	0.44	0.66	0.99	0.7	-0.98		0.66	0.98	0.66	0.85	0.98	0.67	0.06	0.44	0.68	0.87	0.98	0.63	0.52	0.14	-0.57	0.62	-0.06	-0.57
Accounts Payable	-0.82	0.77	0.69	0.87	0.69	0.82	-0.72	0.66		0.68	0.84	0.59	0.67	0.89	0.23	0.63	0.91	0.32	0.74	0.33	0.65	0.26	-0.65	0.9	-0.02	-0.65
Cash	-0.82	0.96	0.43	0.66	0.98	0.68	-1.0	0.98	0.68		0.63	0.87	0.99	0.64	0.0	0.41	0.68	0.85	0.97	0.58	0.47	0.11	-0.5	0.66	-0.12	-0.5
Non Current Assets Total	-0.95	0.77	0.81	0.91	0.7	0.96	-0.68	0.66	0.84	0.63		0.51	0.62	0.87	0.46	0.81	0.91	0.46	0.7	0.5	0.86	0.44	-0.8	0.7	0.14	-0.8
Non Currrent Assets Other	-0.7	0.79	0.14	0.45	0.82	0.45	-0.85	0.85	0.59	0.87	0.51		0.83	0.46	-0.24	0.12	0.5	0.82	0.79	0.5	0.27	-0.22	-0.35	0.69	-0.44	-0.35
Cash And Short Term Investments	-0.81	0.97	0.44	0.68	0.98	0.68	-0.99	0.98	0.67	0.99	0.62	0.83		0.67	0.04	0.44	0.7	0.82	0.99	0.57	0.46	0.15	-0.5	0.64	-0.05	-0.5
Inventory	-0.87	0.78	0.78	0.96	0.7	0.9	-0.69	0.67	0.89	0.64	0.87	0.46	0.67		0.36	0.7	0.97	0.3	0.76	0.27	0.74	0.4	-0.64	0.75	0.14	-0.64
Other Current Assets	-0.32	0.22	0.77	0.5	0.15	0.5	-0.05	0.06	0.23	0.0	0.46	-0.24	0.04	0.36		0.78	0.44	-0.06	0.16	0.26	0.72	0.95	-0.66	0.0	0.85	-0.66
Other Stockholder Equity	-0.7	0.58	0.92	0.81	0.51	0.86	-0.47	0.44	0.63	0.41	0.81	0.12	0.44	0.7	0.78		0.78	0.22	0.54	0.5	0.78	0.79	-0.77	0.4	0.6	-0.77
Total Liab	-0.91	0.81	0.86	0.99	0.72	0.94	-0.73	0.68	0.91	0.68	0.91	0.5	0.7	0.97	0.44	0.78		0.36	0.78	0.31	0.79	0.47	-0.68	0.78	0.18	-0.68
Property Plant And Equipment Gross	-0.66	0.78	0.17	0.34	0.85	0.47	-0.82	0.87	0.32	0.85	0.46	0.82	0.82	0.3	-0.06	0.22	0.36		0.77	0.63	0.35	-0.05	-0.43	0.36	-0.2	-0.43
Total Current Assets	-0.86	0.99	0.55	0.77	0.98	0.76	-0.98	0.98	0.74	0.97	0.7	0.79	0.99	0.76	0.16	0.54	0.78	0.77		0.57	0.57	0.25	-0.59	0.67	0.03	-0.59
Short Long Term Debt Total	-0.53	0.61	0.31	0.3	0.66	0.48	-0.57	0.63	0.33	0.58	0.5	0.5	0.57	0.27	0.26	0.5	0.31	0.63	0.57		0.34	0.26	-0.64	0.29	0.2	-0.64
Current Deferred Revenue	-0.78	0.65	0.85	0.82	0.58	0.84	-0.51	0.52	0.65	0.47	0.86	0.27	0.46	0.74	0.72	0.78	0.79	0.35	0.57	0.34		0.68	-0.84	0.42	0.46	-0.84
Net Receivables	-0.32	0.29	0.8	0.54	0.22	0.52	-0.15	0.14	0.26	0.11	0.44	-0.22	0.15	0.4	0.95	0.79	0.47	-0.05	0.25	0.26	0.68		-0.59	-0.01	0.9	-0.58
Common Stock Total Equity	0.73	-0.68	-0.71	-0.68	-0.64	-0.76	0.52	-0.57	-0.65	-0.5	-0.8	-0.35	-0.5	-0.64	-0.66	-0.77	-0.68	-0.43	-0.59	-0.64	-0.84	-0.59		-0.51	-0.44	1.0
Non Current Liabilities Total	-0.75	0.69	0.44	0.71	0.63	0.66	-0.68	0.62	0.9	0.66	0.7	0.69	0.64	0.75	0.0	0.4	0.78	0.36	0.67	0.29	0.42	-0.01	-0.51		-0.29	-0.51
Short Term Debt	-0.01	0.06	0.57	0.25	0.02	0.26	0.1	-0.06	-0.02	-0.12	0.14	-0.44	-0.05	0.14	0.85	0.6	0.18	-0.2	0.03	0.2	0.46	0.9	-0.44	-0.29		-0.44
Common Stock	0.73	-0.68	-0.71	-0.68	-0.64	-0.77	0.52	-0.57	-0.65	-0.5	-0.8	-0.35	-0.5	-0.64	-0.66	-0.77	-0.68	-0.43	-0.59	-0.64	-0.84	-0.58	1.0	-0.51	-0.44

Click cells to compare fundamentals

USANA Health Account Relationship Matchups

USANA Health fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	22.8M	21.3M	20.3M	19.3M	19.3M	27.4M
Total Assets	516.9M	640.9M	577.7M	596.5M	632.8M	664.4M
Other Current Liab	101.4M	105.0M	104.0M	88.8M	83.5M	57.3M
Total Current Liabilities	136.1M	168.1M	160.8M	143.8M	118.8M	76.4M
Total Stockholder Equity	351.7M	441.7M	395.1M	434.5M	497.2M	522.1M
Property Plant And Equipment Net	95.2M	100.4M	101.8M	97.8M	99.8M	60.0M
Net Debt	(226.5M)	(303.3M)	(232.8M)	(281.5M)	(317.2M)	(301.4M)
Retained Earnings	306.1M	382.8M	344.6M	391.6M	445.2M	467.5M
Accounts Payable	12.5M	18.2M	13.5M	11.0M	10.1M	8.2M
Cash	234.8M	311.9M	239.8M	288.4M	330.4M	346.9M
Non Current Assets Total	187.7M	215.6M	212.6M	212.2M	215.0M	110.8M
Non Currrent Assets Other	40.0M	59.3M	34.1M	51.9M	54.9M	57.6M
Cash And Short Term Investments	234.8M	311.9M	239.8M	288.4M	330.4M	346.9M
Liabilities And Stockholders Equity	516.9M	640.9M	577.7M	596.5M	632.8M	664.4M
Inventory	68.9M	90.2M	98.3M	67.1M	61.5M	40.7M
Other Current Assets	25.5M	15.7M	19.8M	21.7M	18.7M	16.4M
Other Stockholder Equity	59.4M	62.5M	50.0M	55.6M	65.7M	36.1M
Total Liab	165.2M	199.2M	182.6M	162.1M	135.6M	88.4M
Property Plant And Equipment Gross	126.5M	100.4M	101.8M	222.5M	228.8M	240.2M
Total Current Assets	329.3M	425.3M	365.1M	384.4M	417.7M	438.6M
Accumulated Other Comprehensive Income	(13.9M)	(3.6M)	458K	(12.8M)	(13.7M)	(13.0M)
Current Deferred Revenue	13.9M	16.0M	19.6M	20.9M	13.9M	12.0M
Net Receivables	8.8M	7.4M	7.2M	7.2M	7.2M	7.0M
Non Current Liabilities Total	29.1M	31.2M	21.8M	18.2M	16.7M	12.9M
Short Term Debt	8.3M	8.6M	7.1M	6.9M	8.1M	11.9M
Other Assets	26.2M	67.0M	62.7M	50.7M	1.0	0.95
Property Plant Equipment	95.2M	100.4M	101.8M	111.7M	128.4M	68.0M
Other Liab	11.9M	12.0M	21.8M	10.6M	12.1M	7.1M
Good Will	16.6M	17.4M	17.7M	17.4M	17.1M	14.8M
Intangible Assets	29.8M	30.8M	30.4M	32.4M	29.9M	28.3M
Net Tangible Assets	305.2M	441.7M	347.0M	384.7M	442.4M	297.1M
Retained Earnings Total Equity	329.5M	306.1M	382.8M	344.6M	396.3M	258.5M
Capital Surpluse	72.0M	59.4M	62.5M	50.0M	57.5M	67.0M
Deferred Long Term Liab	13.4M	10.3M	12.0M	7.5M	8.6M	10.3M
Non Current Liabilities Other	18.8M	19.2M	14.3M	14.2M	12.2M	7.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether USANA Health Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of USANA Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Usana Health Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Usana Health Sciences Stock:

How To Invest In USANA

Details

Is USANA Stock a good investment?

Details

What is USANA Health's Net Worth?

Details

Largest Personal Care Products Companies

View

Largest Household & Personal Products Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of USANA Health. If investors know USANA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about USANA Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.06)

Earnings Share

2.83

Revenue Per Share

45.085

Quarterly Revenue Growth

(0.06)

Return On Assets

0.0809

The market value of USANA Health Sciences is measured differently than its book value, which is the value of USANA that is recorded on the company's balance sheet. Investors also form their own opinion of USANA Health's value that differs from its market value or its book value, called intrinsic value, which is USANA Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because USANA Health's market value can be influenced by many factors that don't directly affect USANA Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between USANA Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if USANA Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, USANA Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

USANA Capital Surpluse vs Deferred Long Term Liab Analysis

Capital Surpluse vs Deferred Long Term Liab

Capital Surpluse vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Capital Surpluse

Deferred Long Term Liab

USANA Health fundamental ratios Correlations

USANA Health Account Relationship Matchups

High Positive Relationship

High Negative Relationship

USANA Health fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Retained Earnings	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Cash

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Retained Earnings	- 0.98	Net Debt
Net Debt	- 0.97	Total Stockholder Equity
Net Debt	- 0.97	Total Assets